引言近年来，免疫治疗以其激活人体免疫系统对抗癌症的创新机制，掀起了肿瘤治疗的革命性浪潮。其中，针对程序性死亡蛋白1（PD-1）和其配体PD-L1的免疫检查点抑制剂成为了多种癌症的一线治疗方案。然而，尽管它们取得了令人瞩目的成效，但疗效有限的问题仍难以 ...

Center for Drug Evaluation (CDE) has approved Alphamab Oncology’s investigational new drug application (IND) for the ...

Artificial intelligence (AI)-aided analysis of pathology slides showed potential as a predictive biomarker for non-small cell ...

Golden Castle AstraZeneca has grown sevenfold in ten years, Sinopharm and Hengrui have surpassed Sanofi! A big competition between multinational and local ...

A multi-institutional clinical trial led by the University of Navarra, Spain, found that blocking growth differentiation ...